Related News
Home » Metro » Health and Science
GSK launches molecular research into TCM
By Cai Wenjun |
September 6, 2012, Thursday
|
Online Edition
Online Edition
GlaxoSmithKline, a UK-based pharmaceutical multinational, announced today that it will conduct innovative molecular research on traditional Chinese medicine and develop new drugs for the global market.
It is the first time that an international pharmaceutical giant expressed strong interest in TCM and planned to carry out a thorough research on it.
"We don't simply renovate the production skills of TCM, but conduct research from the very start -- from finding effective compounds to developing new drugs," said Zang Jingwu, the head of GlaxoSmithKline's China R&D Center in Shanghai.
"Based on the experiences of practicing TCM in China, we will use molecular compound technology in TCM research and drug development," Zang said.
TCM is hard to promote in foreign countries due to its complex formula and the difficulty of extracting effective compounds and explaining its mechanism, he added.
New drugs developed from TCM will be sold not only in the Chinese market but also in the American and European markets, said Zang, whose R&D center has developed five new neurological medicines which are on clinical trial.
It is the first time that an international pharmaceutical giant expressed strong interest in TCM and planned to carry out a thorough research on it.
"We don't simply renovate the production skills of TCM, but conduct research from the very start -- from finding effective compounds to developing new drugs," said Zang Jingwu, the head of GlaxoSmithKline's China R&D Center in Shanghai.
"Based on the experiences of practicing TCM in China, we will use molecular compound technology in TCM research and drug development," Zang said.
TCM is hard to promote in foreign countries due to its complex formula and the difficulty of extracting effective compounds and explaining its mechanism, he added.
New drugs developed from TCM will be sold not only in the Chinese market but also in the American and European markets, said Zang, whose R&D center has developed five new neurological medicines which are on clinical trial.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
